Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Hum Reprod ; 1(2): 103-6, 1986 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-3558753

RESUMO

This paper describes 18 months' experience of direct chromosome analysis applied to villi aspirated during the first trimester, using a catheter inserted trans-cervically. A total of 325 biopsy samples were analysed, and there was a diagnostic failure in 6 of these cases (1.8%). An abnormal karyotype was detected in 12 cases (3.8%); three of them were chromosome mosaics not confirmed on amniotic fluid cultures drawn between the 16th and 18th week of gestation. Cytogenetic control was performed on fetal tissues after voluntary abortion. There was a karyotype discrepancy between the placenta and the fetus in two cases out of the 12 mentioned above.


Assuntos
Vilosidades Coriônicas/ultraestrutura , Aberrações Cromossômicas/diagnóstico , Cariotipagem/métodos , Diagnóstico Pré-Natal/métodos , Adulto , Transtornos Cromossômicos , Feminino , Humanos , Mitose , Mosaicismo , Gravidez , Trissomia
3.
Cancer Chemother Pharmacol ; 4(2): 129-32, 1980.
Artigo em Inglês | MEDLINE | ID: mdl-7389058

RESUMO

After intensive staging 74 ovarian cancer patients were randomized to two arms balanced for stage and post-surgery residual tumor. The two regimens were CTX 100 mg/day continuously and ADM 50 mg/m2 IV every 4 weeks plus CTX 100 mg/day. The response rates were respectively 42% and 52%. Median survival times were 13 and 14 months. The incidence of side effects was significantly higher in the combination-treatment arm. No other statistical differences were found.


Assuntos
Ciclofosfamida/uso terapêutico , Doxorrubicina/uso terapêutico , Neoplasias Ovarianas/tratamento farmacológico , Adulto , Idoso , Ciclofosfamida/efeitos adversos , Doxorrubicina/efeitos adversos , Quimioterapia Combinada , Feminino , Humanos , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...